The Search for New Approaches to Diagnosing & Treating Cancer

This panel is a discussion on topics relevant to investment in current innovations in the oncology space. Topics the panelists might consider discussing include:

  • The technologies/approaches that investors find the most compelling
  • Whether platform technologies or single assets are preferred for investment/partnerships
  • What criteria do investors use when assessing companies for their portfolio or pipeline

Panelists can discuss the industry-wide changes currently seen, including the advance of personalized medicine and the rise of new therapeutic approaches (CAR-T, oncolytic viruses etc.), and how that is affecting the investing landscape.


Request a Meeting

Steve Yoder, Vice President, Business Development, Taiho Oncology

Steve joined Taiho Oncology Inc. as Vice President, Business Development in June 2020. In this newly created role, he is leading the company’s efforts to in-license and acquire additional oncology marketed products and late-stage development therapeutic candidates for treating solid tumors and hematological malignancies. These partnered assets will be added to Taiho Oncology’s expanding portfolio of internally-discovered candidates and approved products addressing the needs of cancer patients in North America.

Dr. Yoder received his Doctorate of Medicine from the University of Virginia and completed a residency in Internal Medicine at Pennsylvania Hospital in Philadelphia. He subsequently received a Masters of Business Administration in Health Care Management at the Wharton School, University of Pennsylvania. Steve has over 25 years of experience in the biopharmaceutical industry, including work in a variety of roles in Strategic Planning, New Product Development, and Marketing at Pfizer. More recently, he served in leadership roles in Search & Evaluation at both Bristol-Myers Squibb and Celgene Business Development, and has been involved in completing many transactions involving therapeutic candidates and collaborations.

Steve serves on the Board of Directors of Life Sciences Pennsylvania.


Request a Meeting

Anthony Bajoras, Managing Director, Cancer Fund

Anthony Bajoras is the Founder and Manager Director of the Cancer Impact Fund. He also serves as a BioAccel Board Member, manager of their for-profit BioAccelerator investment fund, and is a limited partner in the Arizona Founders Fund.

Request a Meeting

Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy

Named for the 1965 hit song by the Beach Boys, Barbara Ann Lavery has a passion for creativity. Whether she’s transforming the landscapes of Ireland, Iceland, and California into large-scale abstract paintings or finding and funding life-changing opportunities to cure cancer, Lavery is guided by an inspired sense of appreciation for innovation.

“Cell and gene therapies embrace an entirely new paradigm,” says Lavery whose years of experiences with non-profit and for-profit organizations, government agencies, and academic institutions helped build her framework of knowledge in life sciences. “Since its inception, ACGT has led the way in recognizing and advancing revolutionary new ideas that really matter.”

As Chief Program Officer, Lavery is responsible for many ACGT initiatives, including leadership of the Academic Research Program and the Biotechnology Investment Program. “This is my dream job,” says Lavery. “It combines science and research with business development and venture philanthropy in a forward-thinking, non-profit environment that’s dedicated to brilliant people who are finding creative new solutions to some of cancer’s toughest challenges. I love it!”

Request a Meeting

Mark Krul, Partner, Aglaia Oncology Funds

Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia in 2003 he was Program Director of the NDDO Research Foundation. He held several positions with NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 until 1997 Mark was Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 until 1993.

Request a Meeting

Duncan Young, Director, Search and Evaluation Oncology, BD&L, AstraZeneca

Duncan is a Experienced Business Development professional passionate about early innovation and technology, with keen interest new models of collaborative working and open innovation between academia, the charity sector and industry, and supporting and mentoring life science entrepreneurs.

Specialities: Open Innovation, Drug Discovery, Mentoring, Medical Technologies, Technology Transfer, IP Management, Technical Due Diligence and Evaluation, Networking, Agreement Negotiation, Consortia Drafting, Strategy.